Grail Inc
GRAL91.090USD
+2.775+3.14%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.29BMarket Cap
LossP/E TTM
More Details of Grail Inc Company
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Grail Inc Info
Ticker SymbolGRAL
Company nameGrail Inc
IPO dateJun 12, 2024
CEORagusa (Robert)
Number of employees1000
Security typeOrdinary Share
Fiscal year-endJun 12
Address1525 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone18336942553
Websitehttps://grail.com/
Ticker SymbolGRAL
IPO dateJun 12, 2024
CEORagusa (Robert)
Company Executives of Grail Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+9.79%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-34.11%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.32K
+3.57%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.12K
+2.79%
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+9.79%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-34.11%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.32K
+3.57%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.12K
+2.79%
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Screening
34.38M
96.72%
Development Services
1.17M
3.28%
By RegionUSD
Name
Revenue
Proportion
United States
34.21M
96.24%
International
1.34M
3.76%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Screening
34.38M
96.72%
Development Services
1.17M
3.28%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
4.64%
CRCM L.P.
4.62%
Other
71.12%
Shareholders
Shareholders
Proportion
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
4.64%
CRCM L.P.
4.62%
Other
71.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.68%
Investment Advisor/Hedge Fund
21.50%
Hedge Fund
13.43%
Corporation
8.98%
Research Firm
4.26%
Individual Investor
1.06%
Bank and Trust
0.48%
Venture Capital
0.38%
Pension Fund
0.24%
Other
23.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Illumina Inc
4.50M
12.49%
+4.50M
--
Jun 30, 2024
BlackRock Institutional Trust Company, N.A.
2.09M
5.78%
+969.56K
+86.91%
Jun 30, 2025
PRIMECAP Management Company
2.05M
5.7%
+2.71K
+0.13%
Jun 30, 2025
The Vanguard Group, Inc.
1.90M
5.26%
+402.62K
+26.97%
Jun 30, 2025
CRCM L.P.
1.84M
5.11%
-1.80M
-49.45%
Sep 30, 2025
Baker Bros. Advisors LP
1.63M
4.52%
--
--
Jun 30, 2025
Farallon Capital Management, L.L.C.
502.00K
1.39%
+502.00K
--
Jun 30, 2025
State Street Investment Management (US)
1.25M
3.46%
-20.25K
-1.60%
Jun 30, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.88%
+12.86K
+1.25%
Jun 30, 2025
Sessa Capital
786.14K
2.18%
-721.93K
-47.87%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
View more
ROBO Global Healthcare Technology & Innovation ETF
Proportion3.75%
Clough Select Equity ETF
Proportion2.7%
Clough Hedged Equity ETF
Proportion2.53%
Franklin Genomic Advancements ETF
Proportion2.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.08%
State Street SPDR S&P Biotech ETF
Proportion0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.59%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.42%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Grail Inc?
The top five shareholders of Grail Inc are:
Illumina Inc holds 4.50M shares, accounting for 12.49% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.09M shares, accounting for 5.78% of the total shares.
PRIMECAP Management Company holds 2.05M shares, accounting for 5.70% of the total shares.
The Vanguard Group, Inc. holds 1.90M shares, accounting for 5.26% of the total shares.
CRCM L.P. holds 1.84M shares, accounting for 5.11% of the total shares.
Illumina Inc holds 4.50M shares, accounting for 12.49% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.09M shares, accounting for 5.78% of the total shares.
PRIMECAP Management Company holds 2.05M shares, accounting for 5.70% of the total shares.
The Vanguard Group, Inc. holds 1.90M shares, accounting for 5.26% of the total shares.
CRCM L.P. holds 1.84M shares, accounting for 5.11% of the total shares.
What are the top three shareholder types of Grail Inc?
The top three shareholder types of Grail Inc are:
Illumina Inc
BlackRock Institutional Trust Company, N.A.
PRIMECAP Management Company
Illumina Inc
BlackRock Institutional Trust Company, N.A.
PRIMECAP Management Company
How many institutions hold shares of Grail Inc (GRAL)?
As of 2025Q3, 934 institutions hold shares of Grail Inc, with a combined market value of approximately 24.89M, accounting for 69.05% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.56%.
What is the biggest source of revenue for Grail Inc?
In FY2025Q2, the Screening business generated the highest revenue for Grail Inc, amounting to 34.38M and accounting for 96.72% of total revenue.
